> Detailanzeige

Garcia Alfonso, Pilar; Chaves-Conde, Manuel; Munoz, Andres; Salud, Antonia; Garcia-Giron, Carlos; Gravalos Castro, Cristina; Massuti, Bartomeu; González Flores, Encarnación; Queralt, Bernardo; Lopez Ladron, Amelia; Losa, Ferran; Oltra Ferrando, Amparo; Gomez Reina, Maria Jose; Garcia-Carbonero, Rocio; Garcia-Escobar, Ignacio; Aranda, Enrique

Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
  • Beteiligte: Garcia Alfonso, Pilar; Chaves-Conde, Manuel; Munoz, Andres; Salud, Antonia; Garcia-Giron, Carlos; Gravalos Castro, Cristina; Massuti, Bartomeu; González Flores, Encarnación; Queralt, Bernardo; Lopez Ladron, Amelia; Losa, Ferran; Oltra Ferrando, Amparo; Gomez Reina, Maria Jose; Garcia-Carbonero, Rocio; Garcia-Escobar, Ignacio; Aranda, Enrique
  • Erschienen: American Society of Clinical Oncology (ASCO), 2013
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2013.31.4_suppl.501
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 501 </jats:p><jats:p> Background: XELIRI regimen biweekly (combination of capecitabine and irinotecan) is an active and well tolerated treatment for mCRC. Bevacizumab provides significant clinical benefits in previously treated patients with mCRC. On this basis, the aim of this study is to evaluate the efficacy and safety of this combination. Methods: Multicentric, prospective, open-label phase II trial. Treatment scheme: irinotecan (iri) (175mg/m<jats:sup>2</jats:sup> d1 q2w) + capecitabine (xel)(1,000mg/m<jats:sup>2</jats:sup>bid d 2-8) + bevacizumab (bev) (5mg/kg, d1 q2w). Results: 77 patients (p) were evaluated (66.2%, male) with a median age of 65.1 years (41.1-81.1). ECOG performance status was ≤1 in 96.1%. Primary tumor locations were: colon (53.2%), rectum (31.2%), and rectum/colon (15.6%). 27 p (35.1%) received adjuvant chemotherapy. Metastases were detected in liver (62.3%) and lung (54.5%). Mean time in treatment was: 7.1±4.9 months and median of cycles administered was 12(1-43). Median relative dose intensity was 89% for xel and bev and 85% for iri. Best response confirmed were: complete response (5.2%), partial response (32.5%), stable disease (46.8%). After a median of follow-up of 23.3 (0.4-39.6) months, median overall survival (OS) and progression free survival (PFS) was 24.8 and 11.8 months respectively. Analysis on Kras status was done in 71 p. There were no significant differences in OS or in PFS between WT and MUT p. 17 p (22.1%) underwent salvage surgery, 12 of whom had an R0 resection. The most frequent G3-4 toxicities were: diarrhea (18.2%), asthenia (16.9%), pulmonary embolism (13%; in eight of 10 p were asymptomatic), neutropenia (10.4%), febrile neutropenia (6.5%) and HFS (5.2%). Three treatment related deaths were reported (2 cases of multi-organ failure, and 1 case of intestinal perforation). Conclusions: Bevacizumab combined with biweekly XELIRI is an active first-line regimen for mCRC treatment with a feasible and manageable safety profile. Bevacizumab treatment efficacy was independent on Kras status. Clinical trial information: NCT00875771. [Table: see text] </jats:p>
  • Zugangsstatus: Freier Zugang